A randomized trial of therapies for type 2 diabetes and coronary artery disease

New England Journal of Medicine

Volumn 360, Issue 24, 2009, Pages 2503-2515

  Frye, Robert L ^a   August, Phyllis ^b   Brooks, Maria Mori ^c,m   Hardison, Regina M ^c   Kelsey, Sheryl F ^c   MacGregor, Joan M ^c   Orchard, Trevor J ^c   Chaitman, Bernard R ^d   Genuth, Saul M ^e   Goldberg, Suzanne H ^f   Hlatky, Mark A ^g   Jones, Teresa L Z ^h   Molitch, Mark E ⁱ   Nesto, Richard W ^j   Sako, Edward Y ^k   Sobel, Burton E ^l  

^a MAYO CLINIC   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g STANFORD UNIVERSITY   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^l UNIVERSITY OF VERMONT   (United States)

^m UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NITRATE; SULFONYLUREA; TICLOPIDINE; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ANGIOCARDIOGRAPHY; ARTICLE; BEHAVIOR DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETIC COMA; DRUG ELUTING STENT; GLYCEMIC CONTROL; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; FEMALE; HEART INFARCTION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIERS ESTIMATE; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 67149142042     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0805796     Document Type: Article

References (35)

1. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multi-vessel disease. N Engl J Med 1996;335:21725. [Erratum, N Engl J Med 1997;336:147.]
2. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Aubert RE, Ballard DJ, Barrett-Connor E, et al., eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 1995:233-257 (NIH publication no. 95-1468.)
3. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997;30:171-179 (Pubitemid 27357143)
4. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:10149. (Pubitemid 30656008)
5. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006;116:1071-1080
6. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607 (Pubitemid 19004941)
7. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-589 (Pubitemid 28435240)
8. Kronmal RA, Barzilay JI, Tracy RP, Savage PJ, Orchard TJ, Burke GL. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab 2004;89:2852-2858 (Pubitemid 38766376)
9. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780 (Pubitemid 46629127)
10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 [Erratum, N Engl J Med 2007;357:100.] (Pubitemid 46919772)
11. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-1195 (Pubitemid 47403105)
12. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357
13. Detre K, Murphy ML, Hultgren H. Effect of coronary bypass surgery on longevity in high and low risk patients: report from the V.A. Cooperative Coronary Surgery Study. Lancet 1977;2:1243-1245 (Pubitemid 8243367)
14. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563-570 [Erratum, Lancet 1994;344:1446.] (Pubitemid 24267213)
15. Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E, Wallentin L. 5-Year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006;368:998-1004. (Pubitemid 44353692)
16. Lakkis N, Tsyboulev V, Gibson CM, et al. Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol 2002;1:232-237
17. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516 (Pubitemid 46588415)
18. Pepine CJ, Bourassa MG, Chaitman BR, et al. Factors influencing clinical outcomes after revascularization in the Asymptomatic Cardiac Ischemia Pilot (ACIP). J Card Surg 1999;14:1-8. (Pubitemid 30079967)
19. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997;350:461-468 (Pubitemid 27343300)
20. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591 (Pubitemid 351214285)
21. Barsness GW, Gersh BJ, Brooks MM, Frye RL. Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:Suppl 12A:31G-40G. (Pubitemid 44202283)
22. Albu J, Gottlieb SH, August P, Nesto RW, Orchard TJ. Modifications of coronary risk factors. Am J Cardiol 2006;97:Suppl 12A:41G-52G. (Pubitemid 43927487)
23. Magee MF, Isley WL. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:Suppl 12A:20G-30G. (Pubitemid 43927486)
24. Brooks MM, Frye RL, Genuth S, et al. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:Suppl 12A:9G-19G. (Pubitemid 43927485)
25. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J 2008;156:528-536
26. Kim LS, King SB, Kent K. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D trial. J Am Coll Cardiol Intv 2009;2:384-392
27. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-918
28. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581 (Pubitemid 44903861)
29. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865 [Erratum, Lancet 1998;352:1558.]
31. George PB, Tobin KJ, Corpus RA, Devlin WH, O'Neill WW. Treatment of cardiac risk factors in diabetic patients how well do we follow the guidelines? Am Heart J 2001;142:857-863
32. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-723 (Pubitemid 41071193)
33. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
34. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
35. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559